Skip to main content

Advertisement

SpringerLink
Log in

Dalbavancin for the treatment of paediatric infectious diseases

  • Review
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

To review the topics of interest related to the use of dalbavancin in paediatric patients. PubMed was used to search for all of the studies published over the last 15 years using the key word “dalbavancin”. A total of 36 manuscripts were selected, and due to the limited pediatric experience a further research was performed in order to identify clinical trials ongoing. Three studies that concerned children were found in clinicaltrials.gov. This review considers also the manuscripts published on the adult population in order to highlight the gaps requiring further research at pediatric age. Dalbavancin has emerged as a promising agent against resistant Gram-positive invasive infections. It is approved in the United States and Europe for the treatment of adult patients with acute bacterial skin and skin structure infections (SSTIs). Compared to other available antibiotics that are active against multi-resistant bacteria, the advantages of dalbavancin include a lower potential for drug interactions and the possibility of fewer required doses due to a longer half-life. Pharmacokinetic characteristics of dalbavacin are attractive for its clinical impact, especially for children who may avoid prolonged hospitalization and central venous access. However, further studies are needed to establish its appropriate paediatric dosage before it can be licensed for use in newborns and children. For younger patients, at a time when infections due to multidrug-resistant Gram-positive pathogens are increasing, dosage, efficacy and safety data for dalbavancin are needed to ensure the highest antimicrobial efficacy while also minimizing the risk of adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rossolini GM, Mantengoli E, Montagnani F, Pollini S (2010) Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents. Curr Opin Microbiol 13:582–588

    Article  CAS  PubMed  Google Scholar 

  2. Klinker KP, Borgert SJ (2015) Beyond vancomycin: the tail of the lipoglycopeptides. Clin Ther 37:2619–2636

    Article  CAS  PubMed  Google Scholar 

  3. Roberts KD, Sulaiman RM, Rybak MJ (2015) Dalbavancin and oritavancin: an innovative approach to the treatment of Gram-positive infections. Pharmacotherapy 35:935–948

    Article  CAS  PubMed  Google Scholar 

  4. Ramdeen S, Boucher HW (2015) Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother 16:2073–2081

    Article  PubMed  PubMed Central  Google Scholar 

  5. Food and Drug Administration. Drug Trials Snapshot Dalvance (dalbavancin). Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ucm412999.htm. Accessed on 8 Apr 2016

  6. European Medicines Agency. Xydalba authorisation details 2015. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002840/human_med_001848.jsp&mid=WC0b01ac058001d124 Accessed on 8 Apr 2016

  7. Cobos-Carrascosa E, Soler-Palacín P, Nieves Larrosa M et al (2015) Staphylococcus aureus bacteremia in children: changes during eighteen years. Pediatr Infect Dis J 34:1329–1334

    Article  PubMed  Google Scholar 

  8. Ladhani S, Garbash M (2005) Staphylococcal skin infections in children: rational drug therapy recommendations. Paediatr Drugs 7:77–102

    Article  PubMed  Google Scholar 

  9. Jones RN, Sader HS, Flamm RK (2013) Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 75:304–307

    Article  CAS  PubMed  Google Scholar 

  10. Smith JR, Roberts KD, Rybak MJ (2015) Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections. Infect Dis Ther 4:245–258

    Article  PubMed  PubMed Central  Google Scholar 

  11. Jones RN, Schuchert JE, Mendes RE (2016) Dalbavancin activity when tested against Streptococcus pneumoniae isolated in Medical Centers on six continents (2011–2014). Antimicrob Agents Chemother 60(6):3419–3425

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW, Mendes RE (2015) Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis 82:73–77

    Article  CAS  PubMed  Google Scholar 

  13. Dalbavancin for injection for treatment of acute bacterial skin and skin structure infections. NDA 021-883 briefing document. Presented to the FDA Anti-Infective Drugs Advisory Committee 31 March 2014. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM390793.pdf. Accessed on 8 Apr 2016

  14. Citron DM, Tyrrell KL, Goldstein EJ (2014) Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis 79:438–440

    Article  CAS  PubMed  Google Scholar 

  15. Magiorakos AP, Srinivasan A, Carey RB et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281

    Article  CAS  PubMed  Google Scholar 

  16. Biedenbach DJ, Jones RN (2009) Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007). Diagn Microbiol Infect Dis 64:177–184

    Article  CAS  PubMed  Google Scholar 

  17. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW (2014) Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370:2169–2179

    Article  PubMed  Google Scholar 

  18. Mendes RE, Castanheira M, Farrell DJ et al (2016) Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). J Antimicrob Chemother 71:276–278

    Article  CAS  PubMed  Google Scholar 

  19. Malabarba A, Goldstein BP (2005) Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 55(Suppl 2):ii15–ii20

    CAS  PubMed  Google Scholar 

  20. Maffioli SI, Cruz JC, Monciardini P, Sosio M, Donadio S (2016) Advancing cell wall inhibitors towards clinical applications. J Ind Microbiol Biotechnol 43:177–184

    Article  CAS  PubMed  Google Scholar 

  21. Leighton A, Gottlieb AB, Dorr MB et al (2004) Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 48:940–945

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Dorr MB, Jabes D, Cavaleri M et al (2005) Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 55(Suppl 2):ii25–ii30

    CAS  PubMed  Google Scholar 

  23. Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B (2008) Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol 48:1063–1068

    Article  CAS  PubMed  Google Scholar 

  24. Buckwalter M, Dowell JA (2005) Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 45:1279–1287

    Article  CAS  PubMed  Google Scholar 

  25. Cavaleri M, Riva S, Valagussa A et al (2005) Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 55(Suppl 2):ii31–ii35

    CAS  PubMed  Google Scholar 

  26. Cada DJ, Ingram K, Baker DE (2014) Dalbavancin. Hosp Pharm 49:851–861

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Alebic-Kolbah T, Demers R, Cojocaru L (2011) Dalbavancin: quantification in human plasma and urine by a new improved high performance liquid chromatography-tandem mass spectrometry method. J Chromatogr B Analyt Technol Biomed Life Sci 879:2632–2641

    Article  CAS  PubMed  Google Scholar 

  28. Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA (2007) Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 60:681–684

    Article  CAS  PubMed  Google Scholar 

  29. Marbury T, Dowell JA, Seltzer E, Buckwalter M (2009) Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol 49:465–476

    Article  CAS  PubMed  Google Scholar 

  30. Dunne MW, Zhou M, Darpo B (2015) A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents 45:393–398

    Article  CAS  PubMed  Google Scholar 

  31. Bradley JS, Puttagunta S, Rubino CM, Blumer JL, Dunne M, Sullivan JE (2015) Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age. Pediatr Infect Dis J 34:748–752

    Article  PubMed  Google Scholar 

  32. Raad I, Darouiche R, Vazquez J et al (2005) Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 40:374–380

    Article  CAS  PubMed  Google Scholar 

  33. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T (2003) Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 37:1298–1303

    Article  CAS  PubMed  Google Scholar 

  34. Jauregui LE, Babazadeh S, Seltzer E et al (2005) Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41:1407–1415

    Article  CAS  PubMed  Google Scholar 

  35. Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J (2016) A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis 62:545–551

    Article  PubMed  Google Scholar 

  36. Dalbavancin versus active comparator in pediatric subjects with acute hematogenous osteomyelitis. Available at: https://clinicaltrials.gov/ct2/show/NCT02344511?term=dalbavancin&rank=5. Accessed on 6 Apr 2016.

  37. Principi N, Esposito S (2016) Infectious discitis and spondylodiscitis in children. Int J Mol Sci 17(4):539

    Article  PubMed  PubMed Central  Google Scholar 

  38. Principi N, Esposito S (2015) Kingella kingae infections in children. BMC Infect Dis 15:260

    Article  PubMed  PubMed Central  Google Scholar 

  39. Study evaluating the PK profile of dalbavanicn in hospitalized infants and neonates patients with known or suspected bacterial infection. Available at: https://clinicaltrials.gov/ct2/show/NCT02688790?term=dalbavancin&rank=2. Accessed on 6 Apr 2016

  40. Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S (2016) Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf 39:147–157

    Article  CAS  PubMed  Google Scholar 

  41. Bassetti M, Righi E (2016) Safety profiles of old and new antimicrobials for the treatment of MRSA infections. Expert Opin Drug Saf 15:467–481

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Via Commenda 9, 20122, Milan, Italy

    S. Esposito & S. Bianchini

Authors
  1. S. Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Bianchini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Esposito.

Ethics declarations

Funding

This review was supported by a grant from the Italian Ministry of Health (Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Ricerca Corrente Grant 2016 850/01).

Conflict of interest

The authors have nothing to declare.

Ethical approval

All the studies mentioned in this review obtained the approval from the Ethics Committee.

Informed consent

In all the studies mentioned in this review, written informed consent was obtained from patients or patients’ parents or legal guardians.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Esposito, S., Bianchini, S. Dalbavancin for the treatment of paediatric infectious diseases. Eur J Clin Microbiol Infect Dis 35, 1895–1901 (2016). https://doi.org/10.1007/s10096-016-2756-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-016-2756-z

Keywords

Search

Navigation